Abstract: The present invention provides a heating tray for a vacuum hopper precharger, wherein a heating part is configured in a tray having a secondary battery mounted thereon to allow heat generated from the heating part to be circulated inside a vacuum hopper precharger and to be transferred to the entire secondary battery so that the activity of an electrolyte inside the secondary battery is improved, and according thereto, a large amount of residual gas and impurities can be discharged so as to increase purity of the secondary battery. Particularly, the secondary battery can be fully charged with an electrolyte inside the vacuum hopper precharger, thereby improving productivity compared to a conventional configuration in which a secondary battery is charged with an electrolyte at 60% to 70% inside a vacuum hopper precharger and then charged with a remaining charge amount in another process so as to be fully charged.

Abstract: The present invention relates to a benzamide derivative, a preparation method therefor, and a pharmaceutical composition comprising same as an active ingredient for prevention or treatment of cancer. The benzamide derivative provided in an aspect of the present invention can be used for preventing or treating cancer by suppressing EGFR mutation, and exhibits a remarkable synergy effect on anticancer activity when administered in combination with an EGFR antagonist such as Cetuximab, thus finding advantageous uses as an anticancer agent.

Abstract: The present invention relates to a N2,N4-diphenylpyrimidin-2,4-diamine derivative, a method for preparing the same, and a pharmaceutical composition for the prevention or treatment of cancer, containing the same as an active ingredient. The derivative shows a relatively weak EGFR activity inhibitory effect on wild-type EGFR, a high inhibitory ability on EGFR mutation, and a high inhibitory ability on even FLT3 and FLT3 mutation, and thus, can be effectively used for the treatment of cancer with EGFR mutation or cancer with FLT3 or a mutation thereof, and the derivative shows a synergy effect at the time of combination administration, and thus can be effectively used for the treatment of combination administration.

Abstract: The present invention relates to a N2,N4-diphenylpyrimidin-2,4-diamine derivative, a method for preparing the same, and a pharmaceutical composition for the prevention or treatment of cancer, containing the same as an active ingredient. The derivative shows a relatively weak EGFR activity inhibitory effect on wild-type EGFR, a high inhibitory ability on EGFR mutation, and a high inhibitory ability on even FLT3 and FLT3 mutation, and thus, can be effectively used for the treatment of cancer with EGFR mutation or cancer with FLT3 or a mutation thereof, and the derivative shows a synergy effect at the time of combination administration, and thus can be effectively used for the treatment of combination administration.

Abstract: The present invention relates to an isoindolin-1-on derivative, a method for preparing same, and a pharmaceutical composition comprising same as an effective component for preventing or treating tumors, wherein the isoindolin-1-on derivative exhibits a high inhibitory effect on EGFR mutations, and thus can be beneficially used for the treatment of EGFR-mutated tumors, and the isoindolin-1-on derivative exhibits a significant synergistic effect when co-administered, and thus can be beneficially used in concomitant therapy.

Abstract: There is provided a method for enhancing immune function of an immune cell, and an immune cell line produced using the method. A method for enhancing immune function of an immune cell according to an exemplary embodiment of the present invention includes: treating immune cells with a PI3K inhibitor to activate AKT/mTOR downstream signal ex vivo; and culturing the immune cells treated with the PI3K inhibitor such that a lowered AKT level rebounds.

Abstract: The present invention provides a round chip scale package comprising: a light emitting diode for providing blue light from a side surface and an upper surface thereof; and a three-dimensional fluorescent layer arranged to encompass the side surface and the upper surface of the light emitting diode, thereby converting the blue light emitted from the side surface and the upper surface of the light emitting diode into white light, wherein the three-dimensional fluorescent layer comprises a phosphor and silicon, and an edge region of the three-dimensional fluorescent layer is formed into a round shape.

Abstract: Provided are a pharmaceutical composition exhibiting therapeutic efficacy against EML4-ALK-positive non-small cell lung cancer that has acquired resistance to an ALK inhibitor and a method for treating the non-small cell lung cancer. Further, provided is information for drug selection for determining whether to administer a statin-based drug to a patient group with EML4-ALK-positive non-small cell lung cancer.

Abstract: The present invention relates to a N2,N4-diphenylpyrimidin-2,4-diamine derivative, a method for preparing the same, and a pharmaceutical composition for the prevention or treatment of cancer, containing the same as an active ingredient. The derivative shows a relatively weak EGFR activity inhibitory effect on wild-type EGFR, a high inhibitory ability on EGFR mutation, and a high inhibitory ability on even FLT3 and FLT3 mutation, and thus, can be effectively used for the treatment of cancer with EGFR mutation or cancer with FLT3 or a mutation thereof, and the derivative shows a synergy effect at the time of combination administration, and thus can be effectively used for the treatment of combination administration.

Abstract: The present disclosure relates to a novel use of EI24, and provides a novel use of EI24 involved in the improvement of EGFR-TKI drug resistance by inhibiting IGF-1R signaling. According to the present disclosure, the presence or absence of resistance to anti-cancer drugs may be determined by detecting an expression level of EI24. In addition, resistance to anti-cancer drugs may be inhibited, delayed, or improved using EI24 or an activating agent thereof. Moreover, by regulating a pathway of EI24-mediated resistance to anti-cancer drugs, the efficacy of existing anti-cancer drugs may be enhanced, and resistance to anti-cancer drugs may be inhibited, delayed, or improved.

Abstract: Provided are a pharmaceutical composition exhibiting therapeutic efficacy against EML4-ALK-positive non-small cell lung cancer that has acquired resistance to an ALK inhibitor and a method for treating the non-small cell lung cancer. Further, provided is information for drug selection for determining whether to administer a statin-based drug to a patient group with EML4-ALK-positive non-small cell lung cancer.

Abstract: A mucosal dose control radiotherapy apparatus using magnetic fields includes: a radiation generator irradiating radiation toward a tumor region of a patient; a magnetic field generator forming a magnetic field in a body of the patient; and a controller controlling a radiation dose transmitted from the radiation generator to the tumor region of the patient by adjusting a direction and a strength of the magnetic field of the magnetic field generator.

Abstract: The present disclosure relates to a novel use of EI24, and provides a novel use of EI24 involved in the improvement of EGFR-TKI drug resistance by inhibiting IGF-1R signaling. According to the present disclosure, the presence or absence of resistance to anti-cancer drugs may be determined by detecting an expression level of EI24. In addition, resistance to anti-cancer drugs may be inhibited, delayed, or improved using EI24 or an activating agent thereof. Moreover, by regulating a pathway of EI24-mediated resistance to anti-cancer drugs, the efficacy of existing anti-cancer drugs may be enhanced, and resistance to anti-cancer drugs may be inhibited, delayed, or improved.

Abstract: A mucosal dose control radiotherapy apparatus using magnetic fields includes: a radiation generator irradiating radiation toward a tumor region of a patient; a magnetic field generator forming a magnetic field in a body of the patient; and a controller controlling a radiation dose transmitted from the radiation generator to the tumor region of the patient by adjusting a direction and a strength of the magnetic field of the magnetic field generator.

Abstract: A 3-phase inverter module is provided, which includes first and second U-phase switching elements connected in series to each other to constitute a U-phase inverter, first and second V-phase switching elements connected in series to each other to constitute a V-phase inverter, first and second W-phase switching elements connected in series to each other to constitute a W-phase inverter, a U-phase high voltage integrated circuit for generating a control signal for controlling the U-phase inverter according to a U-phase input signal, which has a fault-out terminal for the U-phase, a V-phase high voltage integrated circuit for generating a control signal for controlling the V-phase inverter according to a V-phase input signal, which has a fault-out terminal for the V-phase, and a W-phase high voltage integrated circuit for generating a control signal for controlling the W-phase inverter according to a W-phase input signal, which has a fault-out terminal for the W-phase.

Abstract: A power module for energy recovery and sustain of a plasma display panel is disclosed. The power module includes a first high-voltage integrated circuit which is of a single type, a first switching element for receiving an output from the first high-voltage integrated circuit, and performing a switching operation in response to the output received from the first high-voltage integrated circuit, a first diode connected to one terminal of the first switching element, a second high-voltage integrated circuit which is of a single type, and is arranged symmetrically with the first high-voltage integrated circuit, a second switching element for receiving an output from the second high-voltage integrated circuit, and performing a switching operation in response to the output received from the second high-voltage integrated circuit, and a second diode connected to one terminal of the second switching element.

Abstract: A 3-phase inverter module is provided, which includes first and second U-phase switching elements connected in series to each other to constitute a U-phase inverter, first and second V-phase switching elements connected in series to each other to constitute a V-phase inverter, first and second W-phase switching elements connected in series to each other to constitute a W-phase inverter, a U-phase high voltage integrated circuit for generating a control signal for controlling the U-phase inverter according to a U-phase input signal, which has a fault-out terminal for the U-phase, a V-phase high voltage integrated circuit for generating a control signal for controlling the V-phase inverter according to a V-phase input signal, which has a fault-out terminal for the V-phase, and a W-phase high voltage integrated circuit for generating a control signal for controlling the W-phase inverter according to a W-phase input signal, which has a fault-out terminal for the W-phase.

Abstract: A power module for energy recovery and sustain of a plasma display panel is disclosed. The power module includes a first high-voltage integrated circuit which is of a single type, a first switching element for receiving an output from the first high-voltage integrated circuit, and performing a switching operation in response to the output received from the first high-voltage integrated circuit, a first diode connected to one terminal of the first switching element, a second high-voltage integrated circuit which is of a single type, and is arranged symmetrically with the first high-voltage integrated circuit, a second switching element for receiving an output from the second high-voltage integrated circuit, and performing a switching operation in response to the output received from the second high-voltage integrated circuit, and a second diode connected to one terminal of the second switching element.

Abstract: Provided is an inverter circuit including a switching device which performs a switching operation corresponding to a gate control signal input to a gate terminal, converts an input DC to an AC, and outputs the AC; an HVIC which inputs the gate control signal to the gate terminal of the switching device; a controller which inputs to the HVIC a control signal for enabling the HVIC to generate the gate control signal; a bootstrap circuit which transmits energy to a high-side region of the HVIC; and an impedance cell which is located between the HVIC and one terminal of the switching device to reduce voltage drop of the high-side HVIC.

Abstract: Provided is an inverter circuit including a switching device which performs a switching operation corresponding to a gate control signal input to a gate terminal, converts an input DC to an AC, and outputs the AC; an HVIC which inputs the gate control signal to the gate terminal of the switching device; a controller which inputs to the HVIC a control signal for enabling the HVIC to generate the gate control signal; a bootstrap circuit which transmits energy to a high-side region of the HVIC; and an impedance cell which is located between the HVIC and one terminal of the switching device to reduce voltage drop of the high-side HVIC.